LIBRETTO-431: Confirming the Superiority of Selpercatinib to Chemotherapy and the Lack of Efficacy of Immune Checkpoint Inhibitors in Advanced RET Fusion-Positive (RET+) NSCLC, Another Unique Never-Smoker Predominant Molecular Subtype of NSCLC

Alexandria TM Lee,1 Sai-Hong Ignatius Ou2 1Department of Medicine, University of California Irvine School of Medicine, Orange, CA, 92868, USA; 2Chao Family Comprehensive Cancer Center, Orange, CA, 92868, USACorrespondence: Sai-Hong Ignatius Ou, Department of Medicine, Division of Hematology-Oncology...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Lee ATM, Ou SI
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Dove Medical Press 2024-05-01
Saila:	Lung Cancer: Targets and Therapy
Gaiak:	libretto-431 selpercatinib ret fusion positive nsclc pralsetinib immunotherapy in never-smokers relative dose intensity
Sarrera elektronikoa:	https://www.dovepress.com/libretto-431-confirming-the-superiority-of-selpercatinib-to-chemothera-peer-reviewed-fulltext-article-LCTT
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!